ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone732-902-4000
Debt
Current Ratio1.62
Quick Ratio1.62
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book1.33
Profitability
Net IncomeN/A
Net MarginsN/A
Return on Assets-99.01%
Miscellaneous
Employees21
OptionableNot Optionable
ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions
What is ContraVir Pharmaceuticals' stock symbol?
ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."
When did ContraVir Pharmaceuticals' stock split? How did ContraVir Pharmaceuticals' stock split work?
ContraVir Pharmaceuticals's stock reverse split before market open on Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 28th 2018. An investor that had 100 shares of ContraVir Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.
How were ContraVir Pharmaceuticals' earnings last quarter?
What price target have analysts set for CTRV?
1 brokers have issued twelve-month target prices for ContraVir Pharmaceuticals' shares. Their forecasts range from $32.00 to $32.00. On average, they anticipate ContraVir Pharmaceuticals' stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 8,836.1% from the stock's current price. View Analyst Price Targets for ContraVir Pharmaceuticals.
What is the consensus analysts' recommendation for ContraVir Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraVir Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraVir Pharmaceuticals.
Has ContraVir Pharmaceuticals been receiving favorable news coverage?
News coverage about CTRV stock has been trending positive on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the stock's share price in the next several days.
Are investors shorting ContraVir Pharmaceuticals?
ContraVir Pharmaceuticals saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 368,129 shares, a decline of 36.1% from the December 14th total of 576,453 shares. Based on an average daily volume of 185,457 shares, the short-interest ratio is currently 2.0 days. Approximately 2.3% of the company's stock are sold short. View ContraVir Pharmaceuticals' Current Options Chain.
Who are some of ContraVir Pharmaceuticals' key competitors?
Some companies that are related to ContraVir Pharmaceuticals include Novus Therapeutics (NVUS), SUMMIT THERAPEU/S (SMMT), Nuvo Pharmaceuticals (NRIFF), Kaya (KAYS), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Novelion Therapeutics (NVLN), Xenetic Biosciences (XBIO), Pain Therapeutics (PTIE), Jaguar Health (JAGX), Fibrocell Science (FCSC), RegeneRx Biopharmaceuticals (RGRX), Endonovo Therapeutics (ENDV), Soligenix (SNGX) and KITOV PHARMA LT/S (KTOV).
Who are ContraVir Pharmaceuticals' key executives?
ContraVir Pharmaceuticals' management team includes the folowing people:
- Dr. John Z. Sullivan-Bolyai, Part-Time Consultant & Member of Scientific Advisory Board (Age 70)
- Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., CEO, Chief Scientific Officer & Director (Age 60)
- Mr. John T. Cavan, Chief Financial Officer (Age 60)
- Sharen Pyatetskaya, Director of Investor Relations
How do I buy shares of ContraVir Pharmaceuticals?
Shares of CTRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraVir Pharmaceuticals' stock price today?
One share of CTRV stock can currently be purchased for approximately $0.3581.
How big of a company is ContraVir Pharmaceuticals?
ContraVir Pharmaceuticals has a market capitalization of $5.59 million. ContraVir Pharmaceuticals employs 21 workers across the globe.
What is ContraVir Pharmaceuticals' official website?
How can I contact ContraVir Pharmaceuticals?
ContraVir Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company can be reached via phone at 732-902-4000 or via email at [email protected]
MarketBeat Community Rating for ContraVir Pharmaceuticals (NASDAQ CTRV)
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
